The introduction of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable buzz within the healthcare community. This innovative dual GIP and GLP-1 target medication appears to provide impressive improvements in body loss compared to current therapies. Preliminary patient trials have demonstrated significant declines in weight , co